Understanding how certain factors influence lung cancer development
Official title: Investigating molecular regulators of a mixed-lineage state in lung adenocarcinoma
Funded at University of Utah · NIH-10897198 · Data updated 2026-11-12
This study is looking at how certain proteins in lung cancer cells work together and change to help the cancer grow, with the hope that this information can lead to new treatments for patients with lung adenocarcinoma.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | August 1, 2022 |
| Project end | September 29, 2025 |
| Funding year | 2024 |
| Award (this year) | $39,086 |
| NIH project number | 5F31CA275328-03 |
| Project ID | NIH-10897198 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with lung adenocarcinoma, particularly those exhibiting mixed-lineage characteristics in their tumors.
✕Less likely to help
Patients with other types of lung cancer or those without a diagnosis of lung adenocarcinoma may not benefit from this research.
What this research studies
This research investigates the molecular mechanisms that contribute to the progression of lung adenocarcinoma, the most common type of lung cancer. It focuses on how specific transcription factors, such as NKX2-1 and HNF4α, interact to influence cell differentiation and plasticity in lung cancer cells. By examining these interactions, the research aims to uncover how certain cell states may promote tumor growth and progression. Patients may benefit from insights that could lead to new therapeutic strategies targeting these molecular pathways.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that specifically target the mechanisms driving lung adenocarcinoma progression.
How similar studies have gone: While the specific approach of investigating mixed-lineage states in lung adenocarcinoma is relatively novel, similar research has shown promise in understanding cancer plasticity and progression in other cancer types.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Fort, Gabriela M — University of Utah
- Study coordinator: Fort, Gabriela M
Related research
Other NIH-funded projects on the same topics.
-
Understanding a highly flexible cell state in lung cancer that worsens outcomes
A doctor-scientist at Cedars-Sinai wants to learn how a highly adaptable lung cancer cell state drives disease progression and resistance to therapy, using models that resemble human tumors.
-
Breaking cytokine loops in LKB1-mutant lung cancer and the immune system
A researcher at NYU School of Medicine is studying why a common lung cancer subtype with a specific mutation doesn’t respond well to current immunotherapy, with the aim of finding new ways to improve treatment.
-
Lung Adenocarcinoma: From Genome Changes to New Therapies
This NIH grant supports research on lung adenocarcinoma to better understand its genome changes and translate that knowledge into better diagnosis and treatments for patients.
-
Understanding how lung cancer and immune cells influence each other in early lung cancer development
A study looks at how lung cells and immune cells change together as early lung cancer (lung adenocarcinoma) develops, with the goal of finding points to intervene early.
-
Targeting a cancer pathway to stop metastasis in SMARCA4-deficient lung cancer
This grant aims to understand and interrupt a key pathway that drives spread of a specific type of lung cancer in people whose tumors have SMARCA4 mutations.
-
Combining imaging and biopsy genes to spot aggressive vs. slow-growing early lung cancer before surgery
Aimed at people with early-stage lung adenocarcinoma, this project tests a combined imaging and biopsy gene‑marker approach to better predict tumor aggressiveness before surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.